Lacripep for Neurotrophic Keratopathy

This trial tests Lacripep, an eye solution, to determine its safety and effectiveness for people with Stage 1 neurotrophic keratopathy (NK), a condition affecting the eye's surface that can cause corneal numbness. Researchers aim to understand how Lacripep impacts eye health, vision, and overall quality of life for those with this condition. Participants will receive either Lacripep or a placebo (a solution with no active ingredient). This trial may suit individuals diagnosed with Stage 1 NK in at least one eye who experience issues like reduced corneal sensitivity. As a Phase 2 trial, this research focuses on evaluating the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to significant advancements in eye health.

The trial protocol does not specify if you need to stop taking your current medications. However, you cannot use any non-study issued eye drops or neurostimulators within 14 days before the trial starts.

Studies have shown that Lacripep is generally safe for use. Previous research confirmed its safety for patients with moderate to severe conditions, with very few reports of serious side effects. This suggests that Lacripep can safely treat eye conditions like neurotrophic keratopathy, which affects the cornea. Although researchers are still studying Lacripep for this specific use, its past safety record in other trials offers reassurance for potential participants.¹²³⁴⁵

Most treatments for neurotrophic keratopathy focus on providing artificial tears or ointments to lubricate the eye or, in more severe cases, surgical interventions to protect the cornea. But Lacripep works differently, targeting the underlying problem by using a synthetic peptide designed to promote healing of the corneal nerves. Researchers are excited about Lacripep because it addresses the root cause of the condition rather than just alleviating symptoms, offering the potential for a more effective and long-lasting solution.

Research has shown that Lacripep, which participants in this trial may receive, may help treat eye problems like neurotrophic keratopathy. Studies indicate that Lacripep's artificial tear protein can repair damage to the eye's surface caused by dry eye conditions. Known for its healing ability, it is particularly effective in cases with nerve damage or ongoing eye surface issues. Early evidence suggests it might effectively heal and stabilize the eye surface, improving vision and comfort. Additionally, Lacripep has shown few side effects, with only mild irritation in a small number of patients.¹⁵⁶⁷⁸